Follicular thyroid cancer medical therapy: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NTOC__ {{Follicular thyroid cancer}} {{CMG}}; {{AE}} {{Ammu}} ==Overview== ==Medical Therapy== ===Targeted Therapy=== ====Kinase Inhibitors==== * Sorafenib * Lenvatinib" |
No edit summary |
||
Line 1: | Line 1: | ||
__NoTOC__ | |||
{{Follicular thyroid cancer}} | {{Follicular thyroid cancer}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
Line 6: | Line 6: | ||
===Targeted Therapy=== | ===Targeted Therapy=== | ||
====Kinase Inhibitors==== | ====Kinase Inhibitors==== | ||
* Sorafenib | * Sorafenib | ||
* Lenvatinib | * Lenvatinib |
Revision as of 16:19, 26 October 2015
Follicular thyroid cancer Microchapters |
Differentiating Follicular thyroid cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Follicular thyroid cancer medical therapy On the Web |
American Roentgen Ray Society Images of Follicular thyroid cancer medical therapy |
Risk calculators and risk factors for Follicular thyroid cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Medical Therapy
Targeted Therapy
Kinase Inhibitors
- Sorafenib
- Lenvatinib